We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ocugen Hits A Stumbling Block for Its COVID-19 Vaccine Candidate
Ocugen Hits A Stumbling Block for Its COVID-19 Vaccine Candidate
The FDA has placed a clinical hold on Ocugen’s Investigational New Drug (IND) application for BBV152, the company’s COVID-19 vaccine candidate known as Covaxin outside the U.S.